New drug duo tested for Tough-to-Treat pancreatic cancer
NCT ID NCT03264404
Summary
This study tested whether combining two drugs, pembrolizumab (an immunotherapy) and azacitidine, could help control advanced pancreatic cancer that had worsened after initial chemotherapy. All 36 participants received the drug combination. The goal was to see if this new approach could slow cancer growth and extend the time people lived without their disease getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
Conditions
Explore the condition pages connected to this study.